US$ 22.09
glp-1 news today 2025 obesity drug A nice article in The Hindu today highlights the glp-1 obesity drug market news
Description
This is a worthy read to give a comprehensive presentation as to the risks/benefits as well as the need for vigilance.
*Based on preclinical studies, can support your bodys natural GLP-1 production

Graphical Abstract

CagriSema and Amycretin work on the GLP-1 and amylin receptors, Retrarutide on GLP-1, GIP and glucagon, Survodutide, Mazdutide, Pemvidutide and Efinopegdutide on GLP-1 and glucagon and still more are coming

Listen now | While were away this holiday season, we will be publishing a few of our favourite essays from this year, read out by AI.
Learn what FDA data reveals about GLP-1 medications like Ozempic and Wegovy, their actual side effects, and what really causes night sweats during treatment.